Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Staccato Alprazolam PK/Safety in Healthy Asian and Caucasian Participants
NCT04782388Phase 1Completed
- Sponsor
- UCB
- Start
- Mar 2021
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in epilepsy comparing Staccato alprazolam with Staccato placebo (2 arms). Primary endpoints: Treatment-Emergent Adverse Events at Day 10, Serious Adverse Events at Day 10 and 3 more. Started Mar 2021; status: completed.
02
Drugs
alprazolam
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT04782388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04782388.